Synonyms: SCH 619734 | SCH-619734 | Varubi® | Varuby®
rolapitant is an approved drug (FDA (2015), EMA (2017))
Compound class:
Synthetic organic
Comment: Rolapitant is an orally available neurokinin-1 (NK1) receptor antagonist.
Rolapitant is example 72b in patents US20110098468 [2] and US7049320 B2 [3]. Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
References |
1. Duffy RA, Morgan C, Naylor R, Higgins GA, Varty GB, Lachowicz JE, Parker EM. (2012)
Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets. Pharmacol Biochem Behav, 102 (1): 95-100. [PMID:22497992] |
2. Paliwal S, Reichard GA, Wang C, Xiao D, Tsu H-Ci, Shih N-Y, Arredondo JD, Wrobleski ML, Palani A. (2011)
Nk1 antagonists. Patent number: US20110098468 A1. Assignee: Opko Health, Inc.. Priority date: 18/12/2001. Publication date: 28/04/2011. |
3. Paliwal S, Reichard GA, Wang C, Xiao D, Tsui H-C, Shih N-Y, Arredondo JD, Wrobleski ML, Palani A. (2006)
NK1 antagonists. Patent number: US7049320 B2. Assignee: Schering Corporation. Priority date: 18/12/2001. Publication date: 23/05/2006. |